In the 2010s, vessel co-option was observed in human GBM patients following anti-VEGF therapy with bevacizumab [42,43], contributing to the so-called “infiltrative shift” through which the tumor spreads towards perivascular spaces. This evidence concerns the gene VEGFA and glioblastoma.